The Axial Spondyloarthritis drugs in development market research report provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Axial Spondyloarthritis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Axial Spondyloarthritis and features dormant and discontinued products.
GlobalData tracks 74 drugs in development for Axial Spondyloarthritis by 64 companies/universities/institutes. The top development phase for Axial Spondyloarthritis is phase i with 19 drugs in that stage. The Axial Spondyloarthritis pipeline has 73 drugs in development by companies and one by universities/ institutes. Some of the companies in the Axial Spondyloarthritis pipeline products market are: Johnson & Johnson, Biocad and Gilead Sciences.
The key targets in the Axial Spondyloarthritis pipeline products market include Tumor Necrosis Factor, Interleukin 17A, and Tyrosine Protein Kinase JAK1.
The key mechanisms of action in the Axial Spondyloarthritis pipeline product include Tumor Necrosis Factor Inhibitor with 22 drugs in Pre-Registration. The Axial Spondyloarthritis pipeline products include six routes of administration with the top ROA being Subcutaneous and nine key molecule types in the Axial Spondyloarthritis pipeline products market including Monoclonal Antibody, and Small Molecule.
Axial Spondyloarthritis overview
Axial spondylitis is a type of inflammatory arthritis involving the spine and/or sacroiliac joints. Axial spondylitis is strongly related to the presence of the HLA-B27 gene. A genetic test for HLA-B27 is available.
For a complete picture of Axial Spondyloarthritis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
